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Tyrosine kinase inhibitors represent today’s treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem
cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with
newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for
HSCT and were randomized by availability of a matched family donor between primary HSCT (group A; N= 166 patients) and best
available drug treatment (group B; N= 261). Primary end point was long-term survival. Survival probabilities were not different
between groups A and B (10-year survival: 0.76 (95% conﬁdence interval (CI): 0.69–0.82) vs 0.69 (95% CI: 0.61–0.76)), but inﬂuenced
by disease and transplant risk. Patients with a low transplant risk showed superior survival compared with patients with high-
(Po0.001) and non-high-risk disease (P= 0.047) in group B; after entering blast crisis, survival was not different with or without
HSCT. Signiﬁcantly more patients in group A were in molecular remission (56% vs 39%; P= 0.005) and free of drug treatment (56%
vs 6%; Po0.001). Differences in symptoms and Karnofsky score were not signiﬁcant. In the era of tyrosine kinase inhibitors, HSCT
remains a valid option when both disease and transplant risk are considered.
Leukemia advance online publication, 20 November 2015; doi:10.1038/leu.2015.281
INTRODUCTION
The advent of tyrosine kinase inhibitors (TKIs) has profoundly
changed the outlook for patients with chronic myeloid leukemia
(CML). The majority of patients with this previously fatal disease
achieve a long-lasting clinical, hematological, cytogenetic and, in a
substantial proportion, molecular remission of their disease. Still,
for most patients probably lifelong drug treatment is required.1–3
Hematopoietic stem cell transplantation (HSCT) from an allogeneic
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healthy donor achieves a consistent eradication of the malignant
clone in the majority of patients. On the downside, HSCT is limited
to patients with an available donor and remains associated with
signiﬁcant morbidity and mortality.4,5 Hence, use of HSCT has
changed over the past decade from an early intervention to a
treatment that has been deferred in the lines of therapy.6–8
Current recommendations advise that HSCT should be reserved
for patients who are resistant or intolerant to at least one second-
generation TKI or for patients with blastic phase. HSCT is primarily
considered as a salvage procedure.9,10 There are no prospective
randomized studies to prove this concept. The recommendations
are based on the stunning early results of imatinib compared with
interferon-α-based therapies.1,3,11 They are, in part, supported by
an earlier prospective randomized study from our group where
HSCT was associated with increased early mortality.12
This view might need to be modiﬁed. Transplant-related
mortality has declined, standardization and accreditation have
improved treatment and risk factors for transplant outcome have
been deﬁned.13–15 In a recent study with predetermined criteria,
survival of carefully selected patients with low-risk scores and
allogeneic HSCT was similar to a risk-matched group of patients
treated with imatinib.16 HSCT offers a reasonable option for
patients with advanced disease and low transplant risk, but
outlook for patients transplanted with high transplant risk in
advanced refractory disease remains limited.15,17 With a better
knowledge on risk factors as compared with CML-study III, this
study aimed to look for clinically relevant differences between
early allogeneic HSCT and best drug treatment in patients eligible
for both strategies. Clinically relevant differences comprise higher
probabilities of survival and molecular remission, of living without
treatment, with less symptoms and a higher Karnofsky score.
Supported by prognostic scores, risk groups with a particular
beneﬁt should be identiﬁed.
PATIENTS AND METHODS
Study design
This prospective randomized multicenter CML-study IIIA of the German
CML-study group followed the previously published concept of CML-study
III.12 Patients with newly diagnosed CML were assessed for eligibility to
HSCT (for details see Supplementary eMethods). A suitable patient was
genetically randomized to primary allogeneic HSCT (group A) if a matched
family donor was reported to be available; if no matched family donor was
identiﬁed, the patient was randomized to best available drug treatment
(group B). As a key difference, risk factors associated with allogeneic HSCT
were integrated.14 Teams were urged to perform HSCT within 1 year from
diagnosis. They were instructed to refrain from interferon-α treatment
within 90 days before HSCT to avoid an interferon-associated increase of
non-relapse mortality.18 As a second difference, and according to some
promising preliminary data, autologous SCT was added into the control
arm in an attempt to improve best available drug treatment.19
Patients
Between July 1997 and January 2004, a total of 722 patients were
consecutively registered at the central data management ofﬁce by 143
participating centers (35 university based, 72 municipal hospital based and
36 ofﬁce based)20 (see Supplementary eAcknowledgements). Of these, 669
patients with BCR-ABL-positive CML fulﬁlled the inclusion criteria and
entered the study. All patients considered eligible for transplantation
(n= 427) were randomized within 2 months from registration to group A
(n= 166) or best available drug treatment (group B; n= 261) (Figure 1).
Patients not eligible for HSCT were older and had a higher disease score
compared with the eligible ones; patients in group A were signiﬁcantly
younger (38 vs 41 years; P=0.03) compared with those in group B;
otherwise, no statistically signiﬁcant differences between groups A and B
were observed (Table 1). Patients were analyzed as of May 2014.
Allogeneic HSCT
A total of 305 patients received allogeneic HSCT, 151 patients (144 with a
matched, 7 with a mismatched family donor) in group A, 148 patients in
group B (all with an unrelated donor; 131 in ﬁrst chronic phase (CP), 17 in
advanced phase) and 6 originally non-eligible patients in group C (Figure 1
and Supplementary eTable 1). The median time from diagnosis to
transplantation from a matched related donor was 7 months (range: 2–
33 months). The recommended treatment before HSCT was hydroxyurea.
The source of stem cells was bone marrow for 64 patients (42%) and
peripheral blood for all others. In the 30 centers of four countries,
preparative regimens were classiﬁed according to the CIBMTR (Center for
International Blood and Marrow Transplant Research) functional
deﬁnitions.21 Standard conditioning was applied in 116 patients (77%).
Graft-versus-host disease prophylaxis was primarily cyclosporine
based (62%).
Drug treatment
At the time of recruitment to this study in the pretyrosine kinase inhibitor
era, the recommended primary drug treatment consisted of interferon in
combination with hydroxyurea and low-dose cytosine arabinoside as
described before.12 With its availability, imatinib was offered in the case of
interferon failure or upon request. Over time, a total of 183 patients
received imatinib or a second-generation TKI, 47 in group A (28%) and 136
in group B (84% of 113 patients who did not undergo transplantation and
28% of 148 patients who underwent unrelated donor HSCT). After starting
with imatinib (n= 181), 16 patients switched to dasatinib and 12 patients
to nilotinib.
A total of 44 patients in CP were randomized to autologous HSCT. There
was no difference between autologous HSCT and drug treatment, hence
they were analyzed as ‘drug treatment’.19
Molecular analysis
BCR-ABL transcript levels were determined every 3 months until year 3,
then every 6 months as described previously.22 A major molecular
response was deﬁned by a BCR-ABL/ABL ratio of 0.1 or lower, and a
complete molecular response, by undetectable BCR-ABL transcripts using
total ABL as an internal sensitivity control.
Ethics
The protocol was approved by the ethics committee of the Medical Faculty
Mannheim of the University of Heidelberg and by the local ethics
committees of participating centers. Written informed consent was
obtained from all patients before entering the study. The study protocol
is registered with ClinicalTrials.gov (NCT00025402).
Statistical analysis
Outcome of the groups A and B was analyzed according to the intention-
to-treat principle. Primary end point was survival time from diagnosis.
Secondary end points included ongoing CML therapy, absence of
detectable BCR-ABL transcripts, presence of symptoms and Karnofsky
performance score, all at 10 years after diagnosis. Survival times of patients
in group B who received an unrelated donor HSCT in ﬁrst CP were
censored at the day of transplantation as these transplantations were
performed independent of prior treatment success and early transplant-
related mortality cannot be linked to survival probabilities with best
available drug treatment. Patients undergoing transplantation in acceler-
ated phase or blast crisis were not censored, as drug treatment had failed
before. Survival probabilities were estimated by the Kaplan–Meier method
and compared with the log-rank test. Assuming a late crossing of survival
curves for the main comparison between groups A and B,23 overall survival
and survival after the crossing were compared with the Wilcoxon–Gehan
test. The inﬂuence of HSCT as salvage treatment in blast crisis was analyzed
by Simon–Makuch curves24 and Mantel–Byar test.25 Patients were stratiﬁed
for disease risk by the Euro score26 calculated at diagnosis and for
transplant risk by the European Group for Blood and Marrow Transplanta-
tion (EBMT) score, calculated at the time of allogeneic HSCT.14 To be able
to compare survival probabilities from diagnosis and to avoid time-to-
transplantation bias, adapted EBMT scores were computed for all 427
patients eligible for HSCT. The algorithm for calculation and the
determination of median P-values is given in the Supplementary
eMethods.
The CML-study IIIA
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The signiﬁcance level α was chosen to be 0.05 two-sided. All survival
comparisons within subgroups are understood as explorative analyses;
adjustments for multiple comparisons were not performed. Patients'
characteristics at baseline were descriptively compared using Fisher's test
or Wilcoxon–Mann–Whitney U-test, as appropriate.
Code availability
All analyses were performed with the program package SAS 9.2 (SAS
Institute, Cary, NC, USA).
RESULTS
Survival
Median survival of all 669 patients was not reached. Ten-year
survival probability was 0.61 (95% conﬁdence interval (CI): 0.57–
0.65). Median observation time for living patients was 12.1 years
(range, 7.3–16.1 years). Survival probabilities were better for the
427 patients eligible for HSCT than for the 242 non-eligible
patients (Supplementary eFigure 1a).
Overall and before the crossing of the survival curves at 4.5
years, survival was not signiﬁcantly different between groups A
and B. Before the crossing, 36 patients (22% of 166) in group A
(primary HSCT) died, whereas in group B (best available drug
treatment), 31 (12% of 261) died and 128 (49%) were censored
because of allogeneic HSCT with an unrelated donor in ﬁrst CP
(Figure 2). From 4.5 years on, survival probabilities in group A were
signiﬁcantly higher (Wilcoxon–Gehan test: Po0.001). Ten-year
survival probabilities were 0.76 (95% CI: 0.69–0.82) in group A and
0.69 (95% CI: 0.61–0.76) in group B.
Euro score, EBMT risk score, adapted EBMT risk score and outcome
The Euro score was an appropriate prognostic system for the 261
patients with drug treatment. Patients with low, intermediate or
non-evaluable risk had a signiﬁcantly better survival compared
with the high-risk group (P= 0.002; Supplementary eFigure 1b)
with no signiﬁcant difference between the former groups. The
EBMT risk score was able to discriminate survival within the 151
patients actually transplanted in group A (overall P= 0.002;
Eligible for HSCT (n=427)
Genetic randomisation
Stratification: Eligible for allogeneic hematopoetic
stem cell transplantation (HSCT)? (n=669)
Assessed for eligibility to study (n=722)
Not eligible for HSCT
(n=242), group C   
o Received HSCT (n=6)
o Lost to Follow-up (n=6)*
Excluded (n=53);
o Ph- and BCR-ABL negative CML (n=7), 
o not meeting inclusion criteria (n=46)
Analysis
HSCT with related donor (n=166), group A 
o Received HSCT (n=151);
- in chronic phase (n=144)
- in accelerated or blasic phase (n=7)
o Did not receive HSCT (n=15) 
- death before planned HSCT (n=1)
- development of secondary neoplasia      
before planned HSCT (n=1)
- withdrawal of consent to HSCT (n=13)
Yes No
Best available drug treatment (n=261),
group B
o Received drug treatment (n=130)
o Received HSCT with matched
unrelated donor (MUD) (n=131)
Matched related donor available
Allocation
Lost to follow-up (n=3)*
Discontinued intervention (18 of 130)
o HSCT with MUD in advanced phase 
due to failure of best available drug 
treatment (n=17)
o Discontinued drug treatment (n=1)
Lost to follow-up (n=4)*
Discontinued intervention (n=0 of 151)
Follow up
Analysed (n=166) Analysed (n=261)
*All 669 patients were observed for at least 7.3 years, but 13 (4+3+6) for less than 10.0 years
Figure 1. Consort ﬂow diagram of enrollment, allocation, follow-up and analysis of patients. In group B, all 261 patients started with best
available drug treatment. During the course of disease, 131 patients received an allogeneic HSCT with an unrelated donor in ﬁrst CP. Their
survival time was censored at the day of transplant. Ph, Philadelphia.
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Supplementary eFigure 1c) as well as between all 305 patients
transplanted within the whole patient population (Supplementary
eFigure 1d).
As expected, the adapted EBMT risk score at diagnosis had a
prognostic impact on outcome in group A (Supplementary
eFigure 2a) but not in group B (Supplementary eFigure 2b).
Table 1. Baseline characteristics at diagnosis
Variable, number (n) of evaluable patients Group A:
Eligible for HSCT and
related donor
available
Group B:
Eligible for HSCT
and no related
donor
Group C:
Not eligible
for HSCT
Total Group A vs
group B,
P-value
Groups
A and B
vs group C,
P-value
Number of patients eligible for analysis 166 (25% of 669) 261 (39% of 669) 242 (36% of 669) 669
Median age (years) (range), n= 669 38 (16–58) 41 (13–64) 62 (24–85) 49 (13–85) 0.03 o0.001
Age group at diagnosis, n= 669 0.17 o0.001
% with age o20 years, n= 14 (2% of 669) 3.6 3.1 0 2.1
% with age 20–40 years, n= 218 (33% of 669) 54.8 46.0 2.9 32.6
% with age 440 years, n= 437(65% of 669) 41.6 51.0 97.1 65.3
Euro score, risk group, n= 605 0.34 o0.001
% with low risk, n= 263(43% of 605) 59.5 56.1 19.4 43.5
% with intermediate risk, n= 260 (43% of 605) 32.0 30.4 63.5 43.0
% with high risk, n= 82 (14% of 605) 8.5 13.5 17.1 13.6
% with male sex, n= 669 59.0 65.9 61.2 62.5 0.18 0.62
Median spleen size (cm) bcm (range), n= 617 3 (0–25) 2 (0–30) 0 (0–28) 1 (0–30) 0.51 o0.001
Fatigue, n= 656 48.2 48.8 47.0 48.0 0.92 0.74
Symptoms due to organomegaly, n= 651 25.5 21.3 14.7 20.0 0.34 0.01
% with weight loss of more than 10%, n= 651 19.6 18.0 15.5 17.5 0.70 0.33
% with fever, n= 651 6.8 9.7 3.4 6.8 0.37 0.01
% with extramedullary manifestation, n= 636 3.8 3.2 1.3 2.7 0.78 0.13
Median hemoglobin (g/dl) (range), n= 649 11.6 (5.7–16.4) 11.9 (6.2–17.2) 12.4 (6.4–17.7) 12.2 (5.7–17.7) 0.24 o0.001
Median WBC (countx109/l) (range), n= 650 143 (13–436) 112 (3–613) 83 (8–594) 102 (3–613) 0.16 o0.001
Median PB eosinophils (%) (range), n= 641 2 (0–17) 2 (0–14) 2 (0–12) 2 (0–17) 0.87 0.35
Median PB basophils (%) (range), n= 641 3(0–27) 3 (0–32) 3 (0–27) 3 (0–32) 0.60 0.20
Median PB blasts (%) (range), n= 643 2 (0–18) 1 (0–25) 1 (0–15) 1 (0–25) 0.23 0.04
Median BM blasts (%) (range), n= 426 3 (0–28) 3 (0–30) 3(0–29) 3 (0–30) 0.41 0.23
Median platelet (countx109/l) (range), n= 645 373 (46–1696) 366 (76–2297) 379 (38–4535) 372 (38–4535) 0.57 0.86
Abbreviations: bcm, Below costal margin; BM, bone marrow; HSCT, hematopoietic stem cell transplantation; PB, peripheral blood, WBC, white blood cell.
Year 0 1 2 3 5 7 8 10 12 14
Related donor available 166 157 139 134 130 130 129 122 63 12
No related donor available 261 180 126 115 100 91 88 85 46 9
Patients at risk at different years of observation
Figure 2. Kaplan–Meier estimates of overall survival of the 427 patients stratiﬁed according to genetic randomization. Of 427 patients, 166
were randomized to early allogeneic HSCT (group A) and 261 patients to best available drug treatment (group B). Analysis was performed by
intention to treat. In group B, the survival time of patients receiving an allogeneic HSCT with an unrelated donor was censored at the day of
transplant. The overall survival differences between the two curves were not signiﬁcant (Wilcoxon–Gehan test). At 1, 5 and 10 years, horizontal
crossbars indicate the upper and lower limits of the 95% CIs for the estimated survival probabilities (s.p.).
The CML-study IIIA
A Gratwohl et al
4
Leukemia (2015) 1 – 8 © 2015 Macmillan Publishers Limited
Hence, ﬁve prognostic groups at diagnosis could be differentiated:
three risk groups deﬁned by the adapted EBMT score from
diagnosis for group A and two risk groups deﬁned by the Euro
score in group B (Figure 3a). Patients of group A with adapted
EBMT scores 0–1 (10-year survival probability 0.85 (95% CI: 0.74–
0.92) had signiﬁcantly higher survival probabilities (median
Po0.001) as compared with patients with high-risk Euro score
of group B (10-year survival probability: 0.41 (95% CI: 0.19–0.63))
and also as compared with the 230 non-high-risk patients (median
P= 0.047; 10-year survival probability: 0.73 (95% CI: 0.65–0.80)). In
contrast, there were no statistically signiﬁcant survival differences
of patients in group A with adapted EBMT score 2 (10-year survival
probability: 0.70 (95% CI: 0.58–0.79)) or scores 3–4 (10-year
survival probability: 0.68 (95% CI: 0.45–0.83)) when compared
either with the non-high-risk or the high-risk patients of group B.
Blast crisis occurred in 48 (11%) of the 427 eligible patients. Of
these, 23 received HSCT for treatment of blast crisis. Median time
to transplantation after beginning of blast crisis was 3.6 months.
Thirteen of the 23 patients started with imatinib therapy before
HSCT. Regarding the 25 patients without HSCT in blast crisis, 15
had started imatinib treatment before blast crisis, 6 started
imatinib treatment after blast crisis and 4 have neither received
imatinib nor HSCT. Survival probabilities were not signiﬁcantly
different between patients treated or not with HSCT (Mantel–Byar
test; Figure 3b).
Causes of death
The causes of death differed between groups A and B (Po0.001;
Supplementary eTable 2). Transplant-related mortality was the
most frequent cause of death with 63% of all causes in group A.
Disease progression was the most frequent cause of death in
group B (60%; not considering causes of death if transplanted with
an unrelated donor in ﬁrst CP). Ten percent (group A) and 23%
(group B) of causes of death were reported as not directly related
to the disease or the transplant.
Patient status at 10 years
Concerning all comparative analyses on patient status at 10 years,
the 131 recipients of unrelated donor HSCT in ﬁrst CP were not
considered. Reporting on the 296 remaining patients according to
the intention-to-treat principle, 291 patients (98%) had sufﬁcient
follow-up. At 10 years, 122 (75%) of the 162 patients with a related
donor and 86 (67%) of the 129 patients without related donor
were still alive (Table 2).
At the time of analysis, signiﬁcantly more patients in group A
(56% of 157, (95% CI: 48–64%)) were alive and without CML
treatment than in group B (6% of 127, (95% CI: 2–11%); Po0.001)
and signiﬁcantly more patients in group A (56% of 140, (95% CI:
48–65%)) than in group B (39% of 126, (95% CI: 30–48%);
P= 0.005) were in molecular remission. Details on the kind of
treatment given at 10 years are provided by Supplementary
eTable 3.
There were no signiﬁcant differences between groups A and B
regarding the number of patients with a Karnofsky score below
80% or reporting symptoms.
Patients transplanted in ﬁrst CP with an unrelated donor
In group B, 131 patients were transplanted in ﬁrst CP with an
unrelated donor. Owing to unknown reasons why patients were
selected, the immanent selection of 131 less frail patients
surviving up to the day of transplantation, and ‘guaranteed’
survival between diagnosis and the day of transplantation, an
unbiased comparative analysis between these patients and either
the patients of group A or the 130 patients of group B not
transplanted in ﬁrst CP was not possible. Interpreting their
outcome with this in mind, 10 years after transplantation, 118 of
the 131 patients had either died (n= 54) or were still alive (n= 64,
54%). Fifty percent patients of the 118 patients were without
therapy, 45% with undetectable BCR/ABL, 45% with a Karnofsky
score 480 and 36% without symptoms. Thirteen patients were
alive but not observed for 10 years.
DISCUSSION
Long-term overall survival in this multicenter prospective rando-
mized CML-study IIIA was not different whether patients were
randomized to primary HSCT or to best available drug treatment.
There was no difference in performance status and symptom
reporting between the groups at time of the analysis. However,
signiﬁcantly more patients assigned to early transplant were in
complete molecular remission at 10 years and free of CML
treatment. Outcome was determined by three key factors: disease
risk, transplant risk and treatment allocation. Integrating these
predetermined factors at diagnosis into the intention-to-treat
analysis, patients with HSCT and a low EBMT risk score (0–1)
showed no excess mortality and fared signiﬁcantly better than
patients with no donor. In contrast, the concept of salvage HSCT in
advanced disease despite a high EBMT score failed.
The present data contradict some previous ﬁndings and current
concepts.1,2,9,10 They can be criticized for their relevance in the
times of tyrosine kinase inhibitors, of high-resolution molecular
HLA typing and of availability of more than 20 million typed
unrelated volunteer donors worldwide when outcome after a well-
matched unrelated donor HSCT might be even better than after a
sibling donor transplant.1,27–29 And, the present results are derived
from a study designed 20 years ago in the preimatinib era.
Nevertheless, we consider the main ﬁndings as valid. Outcome
after HSCT can be predicted as has been repeatedly validated.
Risks are approximately additive; outcome is substantially better
for young patients with early disease, a short time interval from
diagnosis and a well-matched, gender identical donor than for
older patients with more advanced disease, a longer time interval
from diagnosis, a mismatched female donor for a male recipient,
independent of stem cell source or transplant technique.14
There are some notes of caution. The results differ substantially
from those of the previous CML-study III.12 This could be explained
by differences in the risk proﬁle of the patients transplanted with a
related donor in ﬁrst CP in group A (144 of 166 patients in CML-
study IIIA).23 Signiﬁcantly improved survival results for these
patients led to a different outcome in the comparison between
groups A and B and thus to different conclusions. In the CML-
study IIIA, transplants had to be performed whenever possible
within 1 year from diagnosis. In addition, outcome of HSCT has
signiﬁcantly improved over the past decade. The majority of the
patients (51%) received imatinib or a second-generation TKI
before transplantation or in the later course of their disease. In a
complex multicenter study involving many participants, patients
and donors, local physicians, CML-study centers and transplant
teams, different opinions prevail. The impact of standardized
strategies in qualiﬁed centers has only recently been
recognized.15,20 Timing was not always consistent, transplant
protocols or drug treatment schedules could have been modiﬁed.
A statistical model can neither adjust for all variables nor consider
a subjective decision for HSCT with an unrelated donor transplant
in ﬁrst CP. However, randomization of patients with a related
donor, analysis in accordance with intention to treat and the use
of an adapted EBMT score at time of diagnosis considerably
reduced the selection and the time-to-transplant bias. Reducing
this bias, results showed no early excess mortality for the
HSCT group.
Outcome of HSCT with high transplant risk score has not
improved over the past decade.15 In our series, the comparative
analysis of the salvage treatment after start of blast crisis was
limited by the small patient number (n= 48) and the unknown
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Year 0 1 2 3 5 7 8 10 12 14
A, EBMT 0-1 68 66 61 60 58 58 58 55 25 2
B, Euro non-high 230 160 113 104 93 85 82 79 45 8
A, EBMT 2 76 72 62 59 57 57 56 52 30 9
A, EBMT 3-4 22 19 16 15 15 15 15 15 8 1
B, Euro high 31 20 13 11 7 6 6 6 1 1
Year 0 1 2 3 5 7 8 10 12
HSCT in blast crisis 0 15 8 8 6 6 6 4 0
No HSCT in blast crisis 48 4 4 2 2 1 1 1 1
Patients at risk at different years of observation
Patients at risk at different years of observation
Figure 3. (a) Kaplan–Meier estimates of overall survival since diagnosis of the 427 patients eligible for allogeneic HSCT with a related donor. At
diagnosis, all 166 patients randomized to group A were stratiﬁed according to the adapted EBMT risk score at diagnosis and all 261 patients
randomized to group B were stratiﬁed according to disease risk (Euro score) at diagnosis. Analysis was performed by intention to treat. In
group B, the survival time of patients receiving an allogeneic HSCT with an unrelated donor was censored at the day of transplant. With EBMT
score 0 or 1 in group A, survival probabilities were signiﬁcantly higher compared with the survival probabilities of Euro high- (log-rank test:
median Po0.001) and Euro non-high-risk patients (log-rank test: median P= 0.047) in group B. At 1 and 5 years, horizontal crossbars indicate
the upper and lower limits of the 95% CIs for the estimated survival probabilities. The abbreviation ‘s.p.’ stands for ’survival probability’.
(b) Simon–Makuch estimates of overall survival of 48 patients with blast crisis. Patients were stratiﬁed according to the reception of allogeneic
HSCT as salvage therapy. All patients started in the non-transplant group. If transplanted, patients changed to the HSCT group at the time of
transplant (ﬁnally, 23 were transplanted). Survival differences were not signiﬁcant (Mantel–Byar test). At 1 year, horizontal crossbars indicate
the upper and lower limits of the 95% CIs for the estimated survival probabilities.
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reasons why some patients were selected for HSCT. Independent
of that, no patient with EBMT risk score 6 or 7 survived long term.
Although the best available drug treatment has meanwhile
considerably improved and a signiﬁcant survival difference with
Euro non-high-risk patients are less likely, the favorable survival
results of the patients with low EBMT score are noteworthy on
their own; in particular, as the results are based on an intention-to-
treat analysis and on a median observation time beyond 10 years.
Without the expense of early excess mortality, patients with newly
diagnosed high-risk CML and non-responders to ﬁrst-line TKI can
beneﬁt from an early low-risk HSCT through improved long-term
survival, shorter time of treatment, a higher rate of molecular
remissions and lower health-care costs. Our data ﬁt with a recent
comparison in the imatinib era. Patients with an early low-risk
HSCT showed no early excess mortality but a signiﬁcantly higher
rate of molecular remissions as compared with those on imatinib
treatment.16 Taken together, these recent data and the results
from this long-term study indicate that patients with a low
transplant score who failed initial tyrosine kinase inhibitors might
be considered for an early HSCT rather than rescue drug
treatment. Assessment of donor availability will be a prerequisite
to achieve this goal; renouncement for HSCT in the absence of a
low-risk donor as well. HSCT for advanced disease with a high
transplant risk should not be advocated; ongoing drug treatment
or best supportive care might be the better option and will also
save costs.30,31 The overall strategy should involve close coopera-
tion between local physicians, treatment centers and transplant
teams. The concept of donor versus no donor should probably
change to a risk-adapted strategy, deﬁned by disease and
transplant risk for acquired hematological disorders in general.
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